126 related articles for article (PubMed ID: 35975976)
1. Design, Synthesis, and Biological Evaluations of Pyridyl 4,5,6,7-Tetrahydro-4,7-Methanobenzo[
Yin L; Pan Y; Xue Y; Chen X; You T; Huang J; Xu Q; Hu Q
J Med Chem; 2022 Sep; 65(17):11876-11888. PubMed ID: 35975976
[TBL] [Abstract][Full Text] [Related]
2. Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.
Brixius-Anderko S; Scott EE
J Biol Chem; 2019 Jan; 294(2):453-460. PubMed ID: 30425102
[TBL] [Abstract][Full Text] [Related]
3. Novel pyridyl- or isoquinolinyl-substituted indolines and indoles as potent and selective aldosterone synthase inhibitors.
Yin L; Hu Q; Emmerich J; Lo MM; Metzger E; Ali A; Hartmann RW
J Med Chem; 2014 Jun; 57(12):5179-89. PubMed ID: 24899257
[TBL] [Abstract][Full Text] [Related]
4. Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton DP
Drugs Today (Barc); 2020 Oct; 56(10):643-654. PubMed ID: 33185629
[TBL] [Abstract][Full Text] [Related]
5. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11beta-hydroxylase) inhibitors.
Müller-Vieira U; Angotti M; Hartmann RW
J Steroid Biochem Mol Biol; 2005 Aug; 96(3-4):259-70. PubMed ID: 15985365
[TBL] [Abstract][Full Text] [Related]
6. A steady state system for in vitro evaluation of steroidogenic pathway dynamics: Application for CYP11B1, CYP11B2 and CYP17 inhibitors.
Mangelis A; Jühlen R; Dieterich P; Peitzsch M; Lenders JWM; Hahner S; Schirbel A; Eisenhofer G
J Steroid Biochem Mol Biol; 2019 Apr; 188():38-47. PubMed ID: 30529282
[TBL] [Abstract][Full Text] [Related]
7. Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
Emmerich J; van Koppen CJ; Burkhart JL; Hu Q; Siebenbürger L; Boerger C; Scheuer C; Laschke MW; Menger MD; Hartmann RW
J Med Chem; 2017 Jun; 60(12):5086-5098. PubMed ID: 28570067
[TBL] [Abstract][Full Text] [Related]
8. Selectivity of osilodrostat as an inhibitor of human steroidogenic cytochromes P450.
Valentín-Goyco J; Liu J; Peng HM; Oommen J; Auchus RJ
J Steroid Biochem Mol Biol; 2023 Jul; 231():106316. PubMed ID: 37098354
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
[TBL] [Abstract][Full Text] [Related]
10. Functional maturation of the primate fetal adrenal in vivo: 3. Specific zonal localization and developmental regulation of CYP21A2 (P450c21) and CYP11B1/CYP11B2 (P450c11/aldosterone synthase) lead to integrated concept of zonal and temporal steroid biosynthesis.
Coulter CL; Jaffe RB
Endocrinology; 1998 Dec; 139(12):5144-50. PubMed ID: 9832454
[TBL] [Abstract][Full Text] [Related]
11. Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.
Peter M; Dubuis JM; Sippell WG
Horm Res; 1999; 51(5):211-22. PubMed ID: 10559665
[TBL] [Abstract][Full Text] [Related]
12. Osilodrostat Is a Potential Novel Steroidogenesis Inhibitor for the Treatment of Cushing Syndrome: An In Vitro Study.
Creemers SG; Feelders RA; de Jong FH; Franssen GJH; de Rijke YB; van Koetsveld PM; Hofland LJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3437-3449. PubMed ID: 31127821
[TBL] [Abstract][Full Text] [Related]
13. Regulation of aldosterone and cortisol production by the transcriptional repressor neuron restrictive silencer factor.
Somekawa S; Imagawa K; Naya N; Takemoto Y; Onoue K; Okayama S; Takeda Y; Kawata H; Horii M; Nakajima T; Uemura S; Mochizuki N; Saito Y
Endocrinology; 2009 Jul; 150(7):3110-7. PubMed ID: 19342457
[TBL] [Abstract][Full Text] [Related]
14. Structural and clinical characterization of CYP11B2 inhibition by dexfadrostat phosphate.
Pignatti E; Kollar J; Hafele E; Schuster D; Steele RE; Vogt B; Schumacher C; Groessl M
J Steroid Biochem Mol Biol; 2023 Dec; 235():106409. PubMed ID: 37827219
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Klein CD; Antes I; Lengauer T; Hartmann RW
J Med Chem; 2005 Mar; 48(5):1563-75. PubMed ID: 15743198
[TBL] [Abstract][Full Text] [Related]
16. Conferring aldosterone synthesis to human CYP11B1 by replacing key amino acid residues with CYP11B2-specific ones.
Böttner B; Denner K; Bernhardt R
Eur J Biochem; 1998 Mar; 252(3):458-66. PubMed ID: 9546661
[TBL] [Abstract][Full Text] [Related]
17. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
[TBL] [Abstract][Full Text] [Related]
18. Structure-Activity Relationships, Pharmacokinetics, and in Vivo Activity of CYP11B2 and CYP11B1 Inhibitors.
Papillon JP; Adams CM; Hu QY; Lou C; Singh AK; Zhang C; Carvalho J; Rajan S; Amaral A; Beil ME; Fu F; Gangl E; Hu CW; Jeng AY; LaSala D; Liang G; Logman M; Maniara WM; Rigel DF; Smith SA; Ksander GM
J Med Chem; 2015 Jun; 58(11):4749-70. PubMed ID: 25953419
[TBL] [Abstract][Full Text] [Related]
19. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability.
Hu Q; Yin L; Ali A; Cooke AJ; Bennett J; Ratcliffe P; Lo MM; Metzger E; Hoyt S; Hartmann RW
J Med Chem; 2015 Mar; 58(5):2530-7. PubMed ID: 25711516
[TBL] [Abstract][Full Text] [Related]
20. The potential of targeting CYP11B.
Bernhardt R
Expert Opin Ther Targets; 2016 Aug; 20(8):923-34. PubMed ID: 26854589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
